NCT03422432View on ClinicalTrials.gov

Prophylactic HIPEC for Colorectal Cancers at High Risk of Developing Peritoneal Metastases

NACompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 28, 2017

Primary Completion Date

September 7, 2023

Study Completion Date

December 13, 2024

Conditions
Colorectal CancerPeritoneal Metastases
Interventions
PROCEDURE

HIPEC

All HIPEC will be with Mitomycin C and given at a dose of 10mg/body surface area.

Trial Locations (1)

169610

National Cancer Centre Singapore, Singapore

All Listed Sponsors
lead

National Cancer Centre, Singapore

OTHER

NCT03422432 - Prophylactic HIPEC for Colorectal Cancers at High Risk of Developing Peritoneal Metastases | Biotech Hunter | Biotech Hunter